Prazosin

(Hypovase*, Prazosin*) POM

- **Client Information Leaflet: Prazosin**
- **Formulations**

Oral: 0.5 mg, 1 mg, 2 mg, 5 mg tablets.

- **Action**

Prazosin is a post-synaptic alpha-1 blocking agent causing arterial and venous vasodilation. This leads to reduction in blood pressure and systemic vascular resistance.

- **Use**
    - Promoting urine flow in patients with functional urethral obstruction, although evidence supporting this is limited.
    - Management of systemic or pulmonary hypertension.
    - Adjunctive therapy of congestive heart failure secondary to mitral or aortic regurgitation in cases refractory to standard therapy (not often used for this indication).

Efficacy may decline over time.

- **DOSES**
    - **Dogs**
        - To decrease urethral resistance in idiopathic vesico-urethral reflex dyssynergia: 1 mg/15 kg p.o. q12h.
        - For adjunctive treatment for heart failure: 1 mg/dog p.o. q8–12h (dogs up to 15 kg); 2 mg/dog p.o. q8–12h (dogs >15 kg). Monitor efficacy by measuring blood pressure and clinical response.
    - **Cats** 0.25–1 mg/cat p.o. q8–12h given initially for 5–7 days then wean off if possible.